Groupe Hospitalier Mutualiste Grenoble
Grenoble, isere, 38000, France
Location status: Recruiting
Location contact
Adrien Monard, ARC
CONTACT
Corinne Camarada, ARC
CONTACT
NCT Number: NCT06988644
Smoking is still a major cause of premature death in France (75,000 deaths a year). Health professionals also seem to be affected by smoking, but few studies have been carried out on this population of smokers. While having a job can be protective, certain working conditions are at risk: night shifts, stress, physical strain, burnout... In 2010, 23% of nurses and 40% of nursing auxiliaries were smokers. More recently, a study of 10,000 health professionals in a French health establishment in 2022 revealed a rate of 32% among nursing auxiliaries.
Data on smoking among health professionals is still scarce. Yet they seem essential, given that smoking among healthcare professionals seems to be an obstacle to dealing with patients' consumption and contributes to the erroneous representations that persist in psychiatry more than elsewhere, such as: "smoking with a patient makes an alliance with them", "smoking is a way of reducing psychological tension", "patients have other problems to deal with", "it won't work because they've been smoking for years". Smoking in mental health facilities is high among both patients and professionals.
Investigators now know that smoking has an impact on mood disorders and sleep. It aggravates all somatic and psychological pathologies and predisposes people to more diabetes, chronic bronchitis, cardiovascular disease, cancer, etc. It also interacts with many drugs.
Smoking screening and cessation assistance have become an indicator of quality somatic care in mental health institutions.
Investigators hypothesise that a consultation in the workplace can help employees to change their smoking habits.
The aims of this study are to assess the effect of a workplace smoking clinic on smokers employed in a mental health institution, and to describe their smoking habits and profiles according to occupational category, with a view to implementing appropriate preventive and treatment measures.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Grenoble, isere, 38000, France
Location status: Recruiting
Adrien Monard, ARC
CONTACT
Corinne Camarada, ARC
CONTACT
Smoking is still a major cause of premature death in France (75,000 deaths a year). Healthcare professionals also seem to be affected by smoking, and few studies have been carried out on this population of smokers.
In 2010, 23% of nurses and 40% of nursing auxiliaries in France said they smoked every day. In a more recent study on parisian hospitals, the prevalence of daily smoking was observed among 26.8% of nurse auxiliaries, 26.3% of nurses, 16.7% of physiotherapists, 27.6% of health managers and 27% of doctors. Among the 3,659 respondents to a study at the Hospices Civils de Lyon, the smoking rate among paramedics (nurses, nursing auxiliaries, and health managers) was 25.6%. Among doctors, pharmacists and dentists, the proportion of smokers is 17.3%, while it reaches 46% among technical and logistics staff. The same survey also showed that paramedical students are three times more likely to be smokers than medical students, and that night staff are 1.5 times more likely to be smokers, given the same age.
In mental health establishments, smoking is prevalent among both patients and healthcare professionals. Investigators now know that smoking affects mood and sleep. It aggravates all pathologies (somatic and psychological) and predisposes people to more diabetes, chronic bronchitis, cardiovascular disease, cancer, etc. It interacts with many psychotropic and analgesic drugs. Smoking screening and cessation assistance have become a quality of care indicator in mental health institutions.
Investigators hypothesise that easier access to smoking cessation consultations in the workplace will improve uptake of this support and encourage smoker carers to change their smoking habits, and that experimenting with this support will increase smoker carers' confidence in their ability to manage their patients' smoking.
The issue of smoking in patients with psychiatric comorbidity is a major one. Smoking significantly reduces their life expectancy: an average of 25 years less, compared with 10 years for smokers without mental disorders. Cardiovascular disease and cancer are the leading causes of premature death. Smoking also affects their quality of life by increasing their metabolic risk (diabetes), reducing their respiratory capacity (chronic obstructive bronchitis) and increasing their risk of chronic disabling pain (arteritis of the lower limbs). Healthcare professionals are expected to play an active role in the fight against smoking and to act as role models for those receiving care, promoting appropriate lifestyles to maintain good health.
Smoking by health professionals does not appear to be more prevalent at the Centre Hospitalier Alpes-Isère than in the general population: 25.9% compared with 25.5%, but this is still significant and probably contributes to the erroneous representations of smoking in psychiatry.
Today, the recommendations of the Haute Autorité de Santé specify that psychological support and assistance are the basis of treatment. Nicotine substitutes supplement this support if the smoker shows signs of nicotine dependence. For smoker health professionals, the offer of smoking counselling in the workplace is likely to encourage them to use these aids and to succeed.
In previous studies, investigators found cessation rates at 12 months of 33% in an intensive intervention group (NST, intensive advice and outpatient telephone follow-up) compared with 20% in a control group (minimal advice) (RR = 1.7; 95% CI: 1.1 to 2.7).
In a study of hospital smoking clinics, 29.5% of patients (schizophrenic patients were excluded) maintained cessation at 1 year: female gender and prematurely interrupted follow-up were significantly associated with the risk of relapse at 1 year.
With regard to smoker healthcare professionals, a meta-analysis published in 2020 of ten studies (6 cohort studies and 4 clinical trials) measured a one-year cessation rate of 21% following the application of pharmacological or behavioural interventions. Hajek et al. showed in a randomised trial that the vaporiser could double the success rate at 1 year compared with treatment with nicotine replacement therapy alone, if accompanied by behavioural support.
Invesigators therefore believe it is possible to achieve a one-year cessation rate of 30% with workplace consultations combining support, nicotine replacement therapy and/or a vapour device where appropriate.
Doctors' smoking status and attitudes towards smoking are known to influence their enthusiasm for advising their patients against smoking.
As the Nagahapitye et al. study made clear: 'It is reasonable to assume that a healthcare professional who is not a smoker or is a former smoker will be more committed and more convincing in spreading messages about smoking and cessation. Health professionals smoking habits are therefore an important factor in the prevention of tobacco-related diseases.
The hypotheses of PSYTaB are :
This study may also highlight benefits for the healthcare establishment and society, notably in terms of reduction in sick leave rates.
This study involves no risk for the subject.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
At the initial tobacco consultation: measurement of exhaled carbon monoxyde. At the tobaccology consultation at 12 months, measurement of the cessation rate: no tobacco smoked in the last 7 days (self-reported), confirmed by a measurement of exhaled carbon monoxyde < 9 ppm.
Time frame: At 12 month
Cessation rate at 12 months: At the 12-month visit, no smoking in the last 7 days (self-reported) confirmed by a measurement of exhaled carbon monoxyde < 9 ppm.
Time frame: at inclusion
Mean Hospital Anxiety and Depression Scale scores To screen for anxiety and depressive symptoms, the following interpretation can be proposed for each of the scores (A and D) Total Score [0;21]
Time frame: at inclusion
Pain numerical scale > 3/10 for 3 months or more
Time frame: at inclusion
Pichot scale, cut-off = 22
Time frame: at inclusion, 6 months and 12 months
Mean Hospital Anxiety and Depression Scale scores To screen for anxiety and depressive symptoms, the following interpretation can be proposed for each of the scores (A and D), Total score [0;21]
Time frame: at inclusion, 6 months and 12 months
Mean Pain Numerical Scale in the last 24 hours. Numerical scale from 0 to 10. Note 0 corresponds to "no pain". Note 10 corresponds to "maximum imaginable pain".
Time frame: at inclusion, 6 months and 12 months
Pichot scale score Total Score [0; 32] A total > 22 indicates excessive fatigue
Time frame: at inclusion , 12 months.
Numerical scale from 0 to 10 (0 means 'I'm absolutely sure I won't make it' and 10 means 'I'm absolutely sure I'll make it')
Time frame: at inclusion, 12 months
Rate of subjects using ancillary products and search for other uses and intentions (cessation or reduction)
Time frame: between inclusion and 12-month follow-up
Number of sick leave days
Time frame: at inclusion
Maslach scale score
The questionnaire thus yields 3 scores:
If both SAP and SD scores are in the red, the risk of Burn-out is very high, especially if the degree of personal fulfillment is also in the red.
Time frame: at inclusion
Data collection: gender, age, profession; level of dependence (Fagerstrom score); level of motivation to smoke and to use cannabis, if applicable (Richmond scale); and level of confidence in managing their patients' tobacco dependence.
Contact information is provided by the study sponsor or research team.
Estelle Cotte-Raffour, Nursery
CONTACT
Laurence Fabaron, Nursery
CONTACT
Groupe Hospitalier Mutualiste de Grenoble
Other
Prospective Study Aimed at Evaluating the Effect of a Counseling Consultation in the Workplace for Smoker Employees in a Mental Health Establishment
Acronym: PSYTaB
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07585357
Behavior, Health Behavior
Baltimore, Maryland, United States
View Trial DetailsNCT06584929
Behavior, Health Behavior
Minneapolis, Minnesota, United States
View Trial DetailsNCT07166120
Behavior, Health Behavior
St Louis, Missouri, United States
View Trial DetailsNCT06651684
Behavior, Chemically-Induced Disorders
Montreal, Quebec, Canada
View Trial Details